Medical Doctor Program year 2021 Reported 2019–2021 Source: CMS Open Payments, 2026 publication

Ronald Passeri

Internal Medicine Salisbury, MD Medical Doctor

NPI 1871582049 CMS profile 130808

31575 Winterplace Pkwy, Salisbury, MD 21804

Open in the dashboard

General payments

$6,634

277 records reported · program years 2019–2021

Research payments

$0

Paid to them · None reported · program years 2019–2021

Ownership & investment interest

$0

None reported

Through program year 2021, Ronald Passeri of Salisbury, MD is reported in the CMS Open Payments database as having received $6,634 across 277 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $2,677 98
2020 General $2,412 111
2019 General $1,546 68

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ronald Passeri
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Ronald Passeri were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Ronald Passeri Internal Medicine median Middle half National median
2019 $1,546 $159 $48–$570 $163
2020 $2,412 $119 $33–$402 $114
2021 $2,677 $135 $37–$521 $132
2022 $0 $141 $42–$496 $149
2023 $0 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2021
  1. Novo Nordisk Inc $1,390 70 payments
  2. AstraZeneca Pharmaceuticals LP $1,115 42 payments
  3. Amgen Inc. $958 25 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $612 37 payments
  5. Lilly USA, LLC $588 31 payments
  6. Sanofi-Aventis U.S. LLC $406 7 payments
  7. AbbVie, Inc. $274 10 payments
  8. Astellas Pharma US Inc $270 12 payments
  9. Pfizer Inc. $180 14 payments
  10. GlaxoSmithKline, LLC. $155 3 payments
  11. Other $686 26 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2021
  1. Food and Beverage $6,155 272 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $380 3 payments
  3. Education $100 2 payments
Products named General payments · program years 2019–2021
  1. Ozempic $859 57 payments
  2. RYBELSUS $769 40 payments
  3. FARXIGA $671 22 payments
  4. AIMOVIG $553 17 payments
  5. JARDIANCE Diabetes $453 25 payments
  6. Repatha $403 15 payments
  7. SOLIQUA 100/33 $336 3 payments
  8. JARDIANCE Diabetes $293 16 payments
  9. BREZTRI $291 11 payments
  10. TRULICITY $267 15 payments
  11. Other $3,237 179 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

277 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record